Literature DB >> 24076756

Prognostic factors associated with decreased survival in patients with acinic cell carcinoma.

David M Neskey1, Jonah D Klein, Stephanie Hicks, Adam S Garden, Diana M Bell, Adel K El-Naggar, Merrill S Kies, Randal S Weber, Michael E Kupferman.   

Abstract

IMPORTANCE: Acinic cell carcinoma is a rare salivary neoplasm that is generally associated with a good prognosis, although a subset of patients develops local and distant recurrences. Given the rarity of the disease, factors to identify patients at risk for recurrences or decreased survival are not clearly defined.
OBJECTIVES: To identify clinicopathologic factors associated with adverse survival in patients with acinic cell carcinoma and to assess the effect of local, regional, and distant recurrences on survival. DESIGN, SETTING, AND PARTICIPANTS: Retrospective medical record review in a tertiary care cancer center of 155 patients treated for acinic cell carcinoma from January 1990 through February 2013. MAIN OUTCOMES AND MEASURES: Primary outcomes evaluated were overall and disease-free survival. The end points assessed were age at diagnosis, sex, size of primary tumor, presence of positive surgical margins, postoperative radiation therapy, and development of local, regional, or distant recurrences.
RESULTS: The median survival was 28.5 years, with 13 patients (8.4%) dying of their disease. Women (n = 104) were affected twice as often as men (n = 51) but had an improved survival (P < .001). Patients diagnosed as having acinic cell carcinoma before or at the age of 45 years had an improved survival (P = .02) compared with their elder counterparts, a finding that was independent of sex. Neoplasms larger than 3 cm at presentation were associated with a decreased overall survival compared with smaller lesions (P = .02). The development of distant metastases was most associated with death from the disease (odds ratio, 49.90; 95% CI, 6.49-2246.30; P < .001) compared with local and regional recurrences. CONCLUSIONS AND RELEVANCE: Although patients with acinic cell carcinoma generally have a favorable prognosis, we have identified several factors associated with decreased survival, including male sex, age older than 45 years, neoplasms larger than 3 cm, and the development of a distant recurrence. These results suggest that maximizing local and regional control for this disease can offer substantial benefit when no distant disease is detectable.

Entities:  

Mesh:

Year:  2013        PMID: 24076756      PMCID: PMC5555308          DOI: 10.1001/jamaoto.2013.4728

Source DB:  PubMed          Journal:  JAMA Otolaryngol Head Neck Surg        ISSN: 2168-6181            Impact factor:   6.223


  9 in total

1.  The superiority of combined therapy (surgery and postoperative irradiation) in parotid cancer.

Authors:  G Tu; Y Hu; P Jiang; D Qin
Journal:  Arch Otolaryngol       Date:  1982-11

2.  Salivary gland cancers, surgery, and irradiation therapy.

Authors:  O M Guillamondegui
Journal:  Arch Otolaryngol       Date:  1982-11

Review 3.  Histopathologic grading of salivary gland neoplasms: II. Acinic cell carcinomas.

Authors:  J G Batsakis; M A Luna; A K el-Naggar
Journal:  Ann Otol Rhinol Laryngol       Date:  1990-11       Impact factor: 1.547

4.  The many faces of acinic cell carcinomas of the salivary glands: a study of 40 cases relating histological and immunohistological subtypes to clinical parameters and prognosis.

Authors:  Stephan Schwarz; Johannes Zenk; Maximilian Müller; Tobias Ettl; Peter H Wünsch; Arndt Hartmann; Abbas Agaimy
Journal:  Histopathology       Date:  2012-05-02       Impact factor: 5.087

Review 5.  The World Health Organization's Histological Classification of Salivary Gland Tumors. A commentary on the second edition.

Authors:  G Seifert; L H Sobin
Journal:  Cancer       Date:  1992-07-15       Impact factor: 6.860

6.  National Cancer Data Base report on cancer of the head and neck: acinic cell carcinoma.

Authors:  H T Hoffman; L H Karnell; R A Robinson; J A Pinkston; H R Menck
Journal:  Head Neck       Date:  1999-07       Impact factor: 3.147

7.  Acinic cell carcinomas arising in salivary glands: a clinicopathologic study.

Authors:  K H Perzin; V A LiVolsi
Journal:  Cancer       Date:  1979-10       Impact factor: 6.860

8.  Update on selected salivary gland neoplasms.

Authors:  Jonathan B McHugh; Daniel W Visscher; E Leon Barnes
Journal:  Arch Pathol Lab Med       Date:  2009-11       Impact factor: 5.534

9.  Adenocarcinoma of salivary origin. Clinicopathologic study of 204 patients.

Authors:  R H Spiro; A G Huvos; E W Strong
Journal:  Am J Surg       Date:  1982-10       Impact factor: 2.565

  9 in total
  9 in total

Review 1.  Salivary acinic cell carcinoma: reappraisal and update.

Authors:  V Vander Poorten; A Triantafyllou; L D R Thompson; J Bishop; E Hauben; J Hunt; A Skalova; G Stenman; R P Takes; D R Gnepp; H Hellquist; B Wenig; D Bell; A Rinaldo; A Ferlito
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-12-19       Impact factor: 2.503

2.  Close Margins and Adjuvant Radiotherapy in Acinic Cell Carcinoma of the Parotid Gland.

Authors:  Joseph Zenga; Anuurag S Parikh; Kevin S Emerick; Derrick T Lin; William C Faquin; Daniel G Deschler
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2018-11-01       Impact factor: 6.223

3.  Ectopic ACTH Production Caused by Metastatic Parotid Gland Acinic Cell Carcinoma.

Authors:  Jacob M Burch; James S Choi; Osama Mosalem; Lawrenshey Charles
Journal:  AACE Clin Case Rep       Date:  2021-01-08

4.  Intensity Modulated Radiotherapy with Carbon Ion Radiotherapy Boost for Acinic Cell Carcinoma of the Salivary Glands.

Authors:  Maximilian P Schmid; Thomas Held; Kristin Lang; Klaus Herfarth; Juliane Hörner-Rieber; Semi B Harrabi; Julius Moratin; Christian Freudlsperger; Karim Zaoui; Jürgen Debus; Sebastian Adeberg
Journal:  Cancers (Basel)       Date:  2021-01-02       Impact factor: 6.639

5.  A Rare Case of Brain Metastasis from Dedifferentiated Acinic Cell Carcinoma of the Parotid Gland and Review of the Literature.

Authors:  Elham Mirzaian; Shafighe Asgari Karchekani; Ashkan Abdoli
Journal:  Iran J Pathol       Date:  2021-08-20

Review 6.  Targeted Therapy, Chemotherapy, Immunotherapy and Novel Treatment Options for Different Subtypes of Salivary Gland Cancer.

Authors:  Sarina K Mueller; Marlen Haderlein; Sebastian Lettmaier; Abbas Agaimy; Florian Haller; Markus Hecht; Rainer Fietkau; Heinrich Iro; Konstantinos Mantsopoulos
Journal:  J Clin Med       Date:  2022-01-29       Impact factor: 4.241

7.  Clinico-Epidemiological Analysis of Most Prevalent Parotid Gland Carcinomas in Poland over a 20-Year Period.

Authors:  Michał Żurek; Kamil Jasak; Karolina Jaros; Piotr Daniel; Kazimierz Niemczyk; Anna Rzepakowska
Journal:  Int J Environ Res Public Health       Date:  2022-08-18       Impact factor: 4.614

Review 8.  Estimating survival after salvage surgery for recurrent salivary gland cancers: Systematic review.

Authors:  Giuditta Mannelli; Lara V Comini; Andrea Sacchetto; Roberto Santoro; Giuseppe Spinelli; Pierluigi Bonomo; Isacco Desideri; Paolo Bossi; Ester Orlandi; Giammarco Alderotti; Alessandro Franchi; Annarita Palomba; Albino Eccher; Daniele Marchioni; Riccardo Nocini; Cesare Piazza; Gabriele Molteni
Journal:  Head Neck       Date:  2022-04-20       Impact factor: 3.821

9.  NR4A3 Immunohistochemistry Reliably Discriminates Acinic Cell Carcinoma from Mimics.

Authors:  Kristine S Wong; Adrian Mariño-Enriquez; Jason L Hornick; Vickie Y Jo
Journal:  Head Neck Pathol       Date:  2020-09-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.